Clinical, biological and genetic characterization of patients.

NA: not available.
*Reference ranges for hormone levels and method characteristics. Total testosterone: 3.5–8.5 ng/mL for adult men (RIA, Orion Diagnostica device, Spectria®, Espoo, Finland; detection limit: 0.01 ng/mL; intra- and interassay coefficients of variation (CVs): 3.2% and 4.6%); estradiol: 15–35 pg/mL for men, <16 for post-menopausal women (RIA, Orion Diagnostica, Spectria®; detection limit: 2 pg/mL; intra- and the interassay CVs: 2.8% and 5.8%); LH: 1.4–8 mU/mL for men, >30 mU/mL for post-menopausal women; FSH: 1.4–10 mU/mL for men, >30 mU/mL for post-menopausal women (for LH and FSH: Immunotech device, Beckman Coulter, Praha, Czech Republic; detection limits: 0.1 IU/L for both FSH and LH; intra- and interassay CVs: <6.3% for FSH, <6.7% for LH); AMH: 22–38 pmol/L for men, 14–48 for women (enzyme immunometric assay, Immunotech reagents, Beckman Coulter Company, Marseille, France; detection limit: 0.4 pmol/L; intra and interassay CVs: <12.3% and <14.2%,); Inhibin B: 80–327 pg/mL for men, <20 pg/mL for post-menopausal women (enzyme immunometric assay, Oxford Bio-Innovation reagents, Serotec, Oxford, UK; detection limit: 15 pg/mL; intra- and interassay CVs: 4.2% and 10.2%,).
**Subjective olfactometry was performed by a computed-assisted validated test [35].